title: Ingenol Mebutate 150 mg as Physician-Directed Treatment of Bowen's Disease Under Occlusion.
abstract: Ingenol mebutate (IM) is a topical pharmacotherapy approved in Switzerland since 2012 for treating non-hypertrophic, non-hyperkeratotic actinic keratosis. We report a case with off-label use of IM where Bowen's disease has been successfully treated with physician-directed IM 0.015% gel under occlusion over the chest area.
authors: Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
authors: Ahmed
authors: A
authors: Alkhalaf
authors: Günther F L
authors: GF
authors: Hofbauer
mesh_terms: D000279:Administration, Cutaneous; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001913:Bowen's Disease / Q000188:drug therapy* / Q000473:pathology; D004224:Diterpenes / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D056687:Off-Label Use; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013909:Thorax
chemical_list: C486592:3-ingenyl angelate; D000970:Antineoplastic Agents; D004224:Diterpenes